Breaking News Instant updates and real-time market news.

TSLA

Tesla

$254.51

-4.19 (-1.62%)

, PTC

PTC

$91.51

-10.43 (-10.23%)

10:16
04/25/19
04/25
10:16
04/25/19
10:16

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Outperform at Wedbush with analyst Daniel Ives saying the demand story is quickly changing and the company has "unfortunately not adjusted to an evolving EV landscape." 2. PTC (PTC) downgraded to Underweight from Neutral at JPMorgan, to Underperform from Neutral at BofA/Merrill, and to Neutral on IoT/AR uncertainties at Wedbush. 3. Xilinx (XLNX) downgraded to Hold from Buy at Needham and to Neutral from Buy at Goldman Sachs. 4. Spirit Airlines (SAVE) downgraded to Neutral from Buy at BofA/Merrill with analyst Andrew Didora saying industry pricing has not improved and sees some cost pressures that limit upside potential. 5. CyberArk (CYBR) downgraded to Neutral from Buy at UBS with analyst Fatima Boolani saying she remains bullish on the company's fundamentals as well as its execution consistency and "expanding mindshare in a market gone mainstream," which have accelerated the company's revenue growth to over 30% and supported the 70% year-to-date run-up in the stock price. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TSLA

Tesla

$254.51

-4.19 (-1.62%)

PTC

PTC

$91.51

-10.43 (-10.23%)

XLNX

Xilinx

$119.70

-20.09 (-14.37%)

SAVE

Spirit Airlines

$52.26

-6.04 (-10.36%)

CYBR

CyberArk

$127.00

1.34 (1.07%)

  • 25

    Apr

  • 14

    May

  • 14

    May

  • 14

    May

  • 21

    May

  • 12

    Jun

  • 13

    Nov

TSLA Tesla
$254.51

-4.19 (-1.62%)

04/25/19
COWN
04/25/19
NO CHANGE
Target $160
COWN
Underperform
Tesla may be entering era of uncertainty, says Cowen
Cowen analyst Jeffrey Osborne says Tesla appears to be entering into an era of uncertainty as a period of normalized demand approaches after enjoying the last 18-24 months of pent up demand for the Model 3 from the deposit list. The analyst sees lower prices as largely indicative of a demand fishing expedition. Even as Tesla reiterated guidance, Osborne believes the company has some of the lowest forward-looking visibility in recent memory. He reiterates an Underperform rating and a $160 price target on the shares.
04/25/19
BOFA
04/25/19
NO CHANGE
Target $225
BOFA
Underperform
BofA says Tesla seems 'amenable' to capital raise after uglier than expected Q1
BofA Merrill Lynch analyst John Murphy said Tesla's "uglier than expected" Q1 results were largely due on an operating basis to weaker deliveries, lower pricing, and lighter gross margins and he revised his estimates to be relatively consistent with the company's outlook and commentary, though he keeps an Underperform rating and $225 price target on the shares. Murphy also said he sees an earnings/cash inflection in the second half as "somewhat questionable." He believes that Elon Musk now "appears amenable" to a capital raise, quoting the CEO as having said "At this point, I do think there is some merit to raising capital." Murphy noted that he does not expect Tesla to turn the corner on free cash flow until after 2020.
04/25/19
JMPS
04/25/19
NO CHANGE
Target $369
JMPS
Outperform
Tesla U.S. demand should recover over course of year, says JMP Securities
JMP Securities analyst Joseph Osha said Tesla's Q1 results were weak, but not more than he expected, and noted that its Q2 outlook was ahead of his previous estimates. The analyst, who thinks following the report that it is "clear that U.S. demand should recover over the course of 2019," believes the company can make money and is an attractive investment if Tesla can hit its volume targets. He lowered his price target on Tesla shares to $369 from $374 but maintains an Outperform rating on the stock.
04/25/19
JEFF
04/25/19
NO CHANGE
Target $400
JEFF
Buy
Jefferies still sees 'path to sustained profitability' for Tesla
Jefferies analyst Philippe Houchois says that beyond last night's headline miss and "ongoing stress," he saw "enough positive surprises from auto gross margin resilience, cash earnings and gross liquidity to argue the shares have sufficiently re-priced." The analyst, who admits his Tesla call is "hard to live with at times," still sees value in the company's electric vehicle/connectivity technology and experimentation. He remains confident "there is a path to sustained profitability." Houchois keeps a Buy rating on Tesla with a $400 price target.
PTC PTC
$91.51

-10.43 (-10.23%)

04/25/19
BOFA
04/25/19
DOWNGRADE
BOFA
Underperform
PTC downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Shankar Subramanian downgraded PTC to Underperform with an $86 price target following lowered bookings guidance for FY19. Subramanian has concerns around execution uncertainty and increasing competitive risks.
04/25/19
STFL
04/25/19
NO CHANGE
Target $105
STFL
Buy
Stifel remains a buyer of PTC despite mixed quarter, guidance cut
Stifel analyst Adam Borg sees PTC shares remaining "in the penalty box" until execution improves but he remains a buyer of the stock as he continues to believe that industry and company-specific drivers and PTC's model transformation "offer plenty of opportunity for low-teens bookings growth and operating margin and FCF expansion." He sees the company's FY19 guidance cut being driven by two related issues, namely that PTC has hired less sales capacity than expected in IoT and AR and that it is seeing lower than expected bookings in the "lower-priority, lower-growth" areas of SLM and ALM. Borg keeps a Buy rating and $105 price target on PTC shares, which are down 10% to $91.32 in pre-market trading.
04/25/19
04/25/19
DOWNGRADE
Target $100

Neutral
PTC downgraded to Neutral on IoT/AR uncertainties at Wedbush
As previously reported, Wedbush analyst Steve Koenig downgraded PTC to Neutral from Outperform, saying that the company's 2019 bookings guidance reduction accompanying its Q2/March print was disappointing, especially after a messy Q1 on large deal execution. Although the analyst likes the risk reduction inherent in the new guide, the appointment of a seasoned finance veteran as CFO, and the return of large PLM deals in Q2, he is stepping to the sidelines on incremental caution concerning the IoT/AR business. Koenig also lowered his price target on the shares to $100 from $104.
04/25/19
BOFA
04/25/19
DOWNGRADE
BOFA
Underperform
PTC downgraded to Underperform from Neutral at BofA/Merrill
XLNX Xilinx
$119.70

-20.09 (-14.37%)

04/25/19
NEED
04/25/19
DOWNGRADE
NEED
Hold
Xilinx downgraded to Hold from Buy at Needham
Needham analyst N. Quinn Bolton downgraded Xilinx to Hold after its Q4 results, saying that while the quarter was "in-line to slightly better", the gross margin guidance for Q1 was "well below" consensus. The analyst adds that although he is impressed with growth in the company's Comms business, he sees a risk to multiple compression on the stock from deceleration in Wireless Comms and the possibility of delayed 5G deployments outside of Korea.
04/25/19
NEED
04/25/19
DOWNGRADE
NEED
Hold
Xilinx downgraded to Hold from Buy at Needham
04/25/19
FBCO
04/25/19
NO CHANGE
Target $135
FBCO
Outperform
Xilinx price target raised to $135 from $110 at Credit Suisse
Credit Suisse analyst John Pitzer raised his price target for Xilinx to $135 from $110 following quarterly results. The analyst reiterates an Outperform rating on the shares.
04/25/19
RHCO
04/25/19
NO CHANGE
Target $126
RHCO
Hold
Xilinx price target raised to $126 from $102 at SunTrust
SunTrust analyst William Stein raised his price target on Xilinx to $126 and also raised his 2020 EPS outlook to $4.22 from $4.08 after its Q4 earnings beat and affirmed 10% long-term sales growth outlook. The analyst is keeping his Hold rating however, citing "solidly" lower than expected Q1 outlook. Stein believes that Xilinx shares are fairly valued, though he adds that he would be "more interested" on a "meaningful reset" in stock price given the company's "longer-term growth potential in datacenter, wireless, and automotive."
SAVE Spirit Airlines
$52.26

-6.04 (-10.36%)

04/25/19
BOFA
04/25/19
DOWNGRADE
BOFA
Neutral
Spirit Airlines downgraded to Neutral from Buy at BofA/Merrill
As previously reported, BofA/Merrill downgraded Spirit Airlines to Neutral from Buy and cut its price target to $61 from $71 following the Q1 revenue miss and Q2 guidance below forecasts. Analyst Andrew Didora said industry pricing has not improved and sees some cost pressures that limit upside potential.
03/28/19
IMPC
03/28/19
NO CHANGE
Target $83
IMPC
Outperform
Spirit Airlines price target lowered to $83 from $92 at Imperial Capital
Imperial Capital analyst Michael Derchin lowered his price target for Spirit Airlines to $83 from $92 to reflect reflect higher fuel prices and conservatism on fiscal 2020 unit revenues. The analyst, however, says Spirit remains his top pick with an Outperform rating. Current share valuations are attractive due to moderate capacity growth, greater yield management capabilities, ancillary revenue growth with key initiatives in the pipeline, cost controls, and "significantly improved" operational reliability resulting in top-tier margins, Derchin tells investors in a research note.
04/02/19
SPHN
04/02/19
NO CHANGE
Target $63
SPHN
Overweight
Airlines needed some good news, and Delta delivered, says Stephens
With investor sentiment on the airline space negative, the group was in need of some good news and Delta Air Lines delivered a positive surprise this morning, Stephens analyst Jack Atkins tells investors in a research note. The airline pointed Q1 RASM growth to the upper-end of its initial guidance range, lowered its Q1 CASM excluding fuel expectation and raised its Q1 earnings guidance range, says the analyst. Atkins finds it encouraging that Delta noted underlying passenger demand remains solid and that the business market led the way during the quarter. Further, the company announced an extension of its credit card partnership with American Express (AXP), which is expected to double the revenue contribution to $7B by 2023 versus 2018 levels, he notes. Atkins reiterates an Overweight rating on Delta with a $63 price target. The stock in midday trading is up 7% to $55.64. Other names in the airline space include Alaska Air (ALK), American Airlines (AAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Continental (UAL).
04/25/19
BOFA
04/25/19
DOWNGRADE
BOFA
Neutral
Spirit Airlines downgraded to Neutral from Buy at BofA/Merrill
CYBR CyberArk
$127.00

1.34 (1.07%)

04/25/19
UBSW
04/25/19
DOWNGRADE
Target $132
UBSW
Neutral
CyberArk downgraded to Neutral from Buy at UBS
UBS analyst Fatima Boolani downgraded CyberArk to Neutral while also raising her price target to $132 from $119. The analyst says she remains bullish on the company's fundamentals as well as its execution consistency and "expanding mindshare in a market gone mainstream", which have accelerated the company's revenue growth to over 30% and supported the 70% year-to-date run-up in the stock price. Boolani notes however that CyberArk stock is now trading about 70% above its historical medians across her valuation metrics and sees its "big beats looking priced in".
03/26/19
MZHO
03/26/19
INITIATION
MZHO
Mizuho initiates security software with top picks Palo Alto, CyberArk, Rapid7
Mizuho analyst Gregg Moskowitz initiated coverage of nine Security Software companies. In his industry update note, titled "Welcome to the New Age of Software - Part II," he noted that "macro concerns remain very prevalent and 4Q tech fundamentals were uneven," but added that he expects "security companies will navigate these issues well, due in part to the fact that cybersecurity consistently ranks at or near the top of IT spending priorities by CIOs." The analyst concluded that "while hardly immune, we would expect security spend to be relatively resilient." Moskowitz noted that global security revenue is currently well in excess of $40B, and growing at a roughly high-single digit CAGR. However, Moskowitz also noted that the security market is very fragmented and contains many sub-segments. He sees four security themes that he believes will become increasingly important, and should help to underpin healthy growth in the sector in the coming years -- Zero Trust, Identity Management, Next-gen Endpoint, and Machine Learning/Automation. The analyst expects to see "generally similar levels of security M&A activity in 2019," although he noted that one variable that could cause this to skew higher would be a large security vendor takeout, which is a historical rarity. Moskowitz initiated three stocks with Buy ratings -- Palo Alto Networks (PANW), CyberArk Software (CYBR), and Rapid7 (RPD) -- and six stocks with Neutral ratings -- Check Point Software (CHKP), FireEye (FEYE), Fortinet (FTNT), Okta (OKTA), Proofpoint (PFPT), and Symantec (SYMC).
03/26/19
MZHO
03/26/19
INITIATION
MZHO
Buy
CyberArk initiated with a Buy at Mizuho
Mizuho analyst Gregg Moskowitz initiated CyberArk with a Buy and $135 price target.
03/19/19
03/19/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Casa Systems (CASA) initiated with a Buy at DA Davidson. 2. Sterling Bancorp (SBT) initiated with an Overweight at Piper Jaffray. 3. Takeda Pharmaceutical (TAK) reinstated with a Buy at Goldman Sachs. 4. CyberArk (CYBR) initiated with an Outperform at FBN Securities. 5. Varex Imaging (VREX) initiated with an Outperform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

YARIY

Yara

$0.00

(0.00%)

20:50
06/16/19
06/16
20:50
06/16/19
20:50
Downgrade
Yara rating change  »

Yara downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTVA

Corteva

$25.20

0.23 (0.92%)

20:49
06/16/19
06/16
20:49
06/16/19
20:49
Upgrade
Corteva rating change  »

Corteva upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$125.30

0.45 (0.36%)

, SNE

Sony

$51.42

1.735 (3.49%)

19:15
06/16/19
06/16
19:15
06/16/19
19:15
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

UTX

United Technologies

$125.30

0.45 (0.36%)

SNE

Sony

$51.42

1.735 (3.49%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GS

Goldman Sachs

$191.71

0.24 (0.13%)

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

BA

Boeing

$347.19

-1.54 (-0.44%)

RTN

Raytheon

$177.38

0.195 (0.11%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 23

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

GM

General Motors

$35.66

-0.36 (-1.00%)

18:49
06/16/19
06/16
18:49
06/16/19
18:49
Periodicals
GM won't deploy self-driving fleet until safer than human driver, Axios reports »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

T

AT&T

$32.36

0.06 (0.19%)

, CMCSA

Comcast

$42.31

0.62 (1.49%)

17:58
06/16/19
06/16
17:58
06/16/19
17:58
On The Fly
Box Office Battle: 'Men in Black: International' wins weekend with just $28.5M »

Sony’s (SNE) "Men in…

T

AT&T

$32.36

0.06 (0.19%)

CMCSA

Comcast

$42.31

0.62 (1.49%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.42

1.735 (3.49%)

LGF.A

Lionsgate

$12.22

-0.85 (-6.50%)

DIS

Disney

$141.64

-0.09 (-0.06%)

VIAB

Viacom

$29.38

-0.28 (-0.94%)

VIA

Viacom

$34.61

0.14 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 24

    Jul

  • 25

    Jul

  • 08

    Aug

  • 08

    Aug

GS

Goldman Sachs

$191.71

0.24 (0.13%)

17:43
06/16/19
06/16
17:43
06/16/19
17:43
Periodicals
Goldman Sachs combining private-investing units, WSJ reports »

Goldman Sachs is pulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

DB

Deutsche Bank

$6.79

-0.07 (-1.02%)

17:38
06/16/19
06/16
17:38
06/16/19
17:38
Periodicals
Deutsche Bank to set up EUR50B bad bank, Financial Times reports »

Deutsche Bank is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$87.10

(0.00%)

16:35
06/16/19
06/16
16:35
06/16/19
16:35
Periodicals
Tires blow on United jet during Newark airport landing, Reuters reports »

Tires on a United…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$87.83

-0.48 (-0.54%)

16:33
06/16/19
06/16
16:33
06/16/19
16:33
Periodicals
Target registers back online after outage blamed on tech issue, Reuters says »

Target said its payment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$46.18

-0.54 (-1.16%)

16:30
06/16/19
06/16
16:30
06/16/19
16:30
Hot Stocks
Intel announces program for Israeli startups targeting tech inflections »

Intel announced a program…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 25

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:27
06/16/19
06/16
16:27
06/16/19
16:27
Periodicals
Boeing says will take time to rebuild customer confidence, Reuters reports »

The head of Boeing said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

GS

Goldman Sachs

$191.71

0.24 (0.13%)

16:19
06/16/19
06/16
16:19
06/16/19
16:19
Periodicals
Goldman Sachs skeptical of 'insurance' rate cuts from Fed, Reuters says »

Goldman Sachs economists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 16

    Jul

BA

Boeing

$347.19

-1.54 (-0.44%)

16:16
06/16/19
06/16
16:16
06/16/19
16:16
Periodicals
Trials nearing for Boeing 737 Max fix, WSJ reports »

The Federal Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

ESLT

Elbit Systems

$154.55

0.55 (0.36%)

13:41
06/16/19
06/16
13:41
06/16/19
13:41
Hot Stocks
Elbit Systems awarded $50M contract »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$176.09

-0.74 (-0.42%)

13:40
06/16/19
06/16
13:40
06/16/19
13:40
Hot Stocks
Amgen announces BLINCYTO five-year overall survival data »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

SILK

Silk Road Medical

$44.80

-0.95 (-2.08%)

13:35
06/16/19
06/16
13:35
06/16/19
13:35
Hot Stocks
Silk Road Medical announces final results for ROADSTER-2 study »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 26

    Aug

EDIT

Editas Medicine

$21.72

-0.78 (-3.47%)

13:30
06/16/19
06/16
13:30
06/16/19
13:30
Hot Stocks
Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.90

-0.055 (-5.79%)

13:28
06/16/19
06/16
13:28
06/16/19
13:28
Hot Stocks
Sunesis announces preliminary data from Phase 1b/2 trial of Vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

APLS

Apellis

$21.22

-0.14 (-0.66%)

13:23
06/16/19
06/16
13:23
06/16/19
13:23
Hot Stocks
Apellis presents data from ongoing Phase 2 PLAUDIT study of APL-2 »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FTSV

Forty Seven

$10.55

-0.02 (-0.19%)

13:16
06/16/19
06/16
13:16
06/16/19
13:16
Hot Stocks
Forty Seven announces data from Phase 1b/2 trial of 5F9 in combo with Rituximab »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

13:06
06/16/19
06/16
13:06
06/16/19
13:06
Hot Stocks
AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

STRO

Sutro Biopharma

$11.17

-0.34 (-2.95%)

13:02
06/16/19
06/16
13:02
06/16/19
13:02
Hot Stocks
Sutro Biopharma announces interim Phase 1 safety data for STRO-001 »

Sutro Biopharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMC

Blueprint Medicines

$90.65

-0.35 (-0.38%)

12:59
06/16/19
06/16
12:59
06/16/19
12:59
Hot Stocks
Blueprint Medicines presents updated EXPLORER trial data for Avapritinib »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.